enterococcus faecalis (clinical strains) (China Pharmaceuticals Inc)
Structured Review

Enterococcus Faecalis (Clinical Strains), supplied by China Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enterococcus+faecalis+(clinical+strains)/enterococcus+faecalis++clinical+strains+/pmc06060096-128-24-29
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides"
Article Title: Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides
Journal: Scientific Reports
doi: 10.1038/s41598-018-29566-5
Figure Legend Snippet: Antibacterial activity of short peptides, parental peptide, and designed peptides (MIC μg/ml).
Techniques Used: Activity Assay, Positive Control
Related Articles
Activity Assay:Article Title: Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides Article Snippet: mass was confirmed by mass spectrometry. .. The experimentally determined strains are as follows: Listeria monocytogenes (ATCC 19115), Staphylococcus aureus (CMCC(B)26003), Bacillus subtilis (CMCC(B)63501), Escherichia coli (CMCC(B) 44102), Pseudomonas aeruginosa (CMCC(B)10104), Positive Control:Article Title: Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides Article Snippet: mass was confirmed by mass spectrometry. .. The experimentally determined strains are as follows: Listeria monocytogenes (ATCC 19115), Staphylococcus aureus (CMCC(B)26003), Bacillus subtilis (CMCC(B)63501), Escherichia coli (CMCC(B) 44102), Pseudomonas aeruginosa (CMCC(B)10104), |